Avexa's commercial strategy is to focus on realizing the value in its internal projects in the area of anti-infectives by achieving definitive, well established milestones for each project. Avexa aims to progress its projects as far as possible (at least to the end of proof-of-concept in man) to add maximum value but would consider discussions with potential partners for collaborations in specific areas to expedite project progress.
Avexa has an extensive foundation of experience in anti-infective drug discovery and development and is keen to exploit its expertise through new collaborations in the anti-infectives area. Avexa has much to offer and would be pleased to explore specific opportunities for collaboration on new anti-infectives research projects, particularly in the anti-viral space.
Avexa believes its expertise in drug development coupled with its passion to advance anti-infectives projects as effectively as possible make Avexa an excellent choice for projects in need of focused development. Avexa would be pleased to discuss what we can offer an external project, ranging from playing a limited role, co-development, risk sharing, or full in-licensing.